Blood and skin cell transcriptomes revealed a JAK-STAT signaling and human herpesvirus targets in an individual with refractory drug-induced hypersensitivity syndrome.
The test is designed to analyze the expression of 17 genes in order to differentiate mild and aggressive forms of Crohn's disease and ulcerative colitis.
The company has raised $30 million to date to fund development and commercialization of its molecular diagnostic test to predict response to anti-TNF therapies.
Investigators analyzed the expression of protein-coding genes in 18 blood immune cell populations, comparing the expression profiles with those in other cell and tissue types.
The firm also recently released the results of collaborations with Admera Health and RareCyte that used its multiplex PCR-based target enrichment technology.
Under the deal, KSL will commercialize and facilitate orders of the PredictSURE IBD test throughout North America and will also process all samples through its laboratory, KSL Diagnostics.
Under the expanded deal, PredictImmune will have first right of refusal on technologies for predicting disease outcome for systemic lupus erythematosus.
The immune sequencing firm is working on kit-ifying its two existing tests, as well as developing a second clinical test and expanding the label for clonoSeq.
Addenbrooke' Hospital will manage and facilitate the fulfillment orders of the firm's PredictSure IBD orders, as well as receive and process all samples.
Investigators calculated that the new assay, which includes 67 SNPs, could offer a 50 percent improvement over previous methods if used in newborn screening.
The company believes it can provide tests to predict patients' responsiveness to specific drugs akin to the molecular diagnostics that have now swelled the oncology space.
The test is a 15-biomarker quantitative PCR panel used to stratify patients with Crohn's disease and ulcerative colitis based on the severity of their illness.
The researchers hope the datasets from their study can help to explain the effects of disease-associated variants on specific cell types of the immune system.
Researchers used fine mapping and other approaches to prioritize proposed coding and non-coding causal variants at rheumatoid arthritis- and type 1 diabetes-linked loci.
These differentially variable positions appear to implicate stress response in rheumatoid arthritis development and possibly in other autoimmune conditions.
The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.
